Video Experimental Relacionado
Updated: Aug 15, 2026

09:36
Changes in Mammary Gland Morphology and Breast Cancer Risk in Rats
Published on: October 16, 2010
La exposición de ratas recién nacidas a compuestos farmacológicamente activos puede alterar permanentemente el
Resumen
La exposición perinatal al fenobarbital en ratas altera la actividad de las enzimas hepáticas y los adductos de aflatoxina B1 en los machos adultos, lo que sugiere una relación con el riesgo de cáncer.
Área de la Ciencia:
- Toxicología Toxicología.
- Biología del desarrollo Biología del desarrollo.
- La carcinogénesis es la carcinogénesis
Sus antecedentes:
- Las enzimas hepáticas microsomales de función mixta oxidasa (MFO) son cruciales para el metabolismo de los xenobióticos.
- La exposición perinatal a ciertos compuestos puede provocar efectos a largo plazo en la salud.
- La aflatoxina B1 es un conocido hepatocarcinógeno que requiere activación metabólica.
Objetivo del estudio:
- Investigar los efectos a largo plazo de la exposición perinatal al fenobarbital en la actividad del MFO.
- Para determinar si la exposición perinatal al fenobarbital influye en la formación de adductos de aflatoxina B1 en la descendencia adulta.
- Evaluar el vínculo potencial entre la exposición perinatal a drogas y el riesgo de cáncer.
Principales métodos:
- A las ratas embarazadas se les administró fenobarbital durante el inicio de la lactancia.
- La actividad hepática MFO se midió en la descendencia masculina adulta.
- Los adductos de aflatoxina B1 se cuantificaron en el hígado de crías adultas de sexo masculino.
Principales resultados:
- La administración de fenobarbital dio lugar a alteraciones a largo plazo en la actividad hepática MFO en la descendencia masculina adulta.
- Las crías expuestas perinatalmente al fenobarbital mostraron un aumento en la formación de adductos de aflatoxina B1.
- Estos cambios eran potencialmente permanentes.
Conclusiones:
- La exposición perinatal al fenobarbital puede inducir cambios duraderos en los sistemas de enzimas que metabolizan el fármaco.
- La actividad alterada del MFO puede aumentar la susceptibilidad a los carcinógenos como la aflatoxina B1.1.
- La exposición perinatal a compuestos farmacológicamente activos puede influir en el riesgo de cáncer a largo plazo.
Más Videos Relacionados
Videos de Conceptos Relacionados
Teratogenicity
The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Factors Affecting Drug Biotransformation: Physicochemical and Chemical Properties of Drugs
A drug's physicochemical properties fundamentally influence its metabolism. For instance, a drug's molecular size and shape critically determine its interaction with enzymes and transporters — larger drugs may face difficulty reaching enzyme active sites, altering their metabolic pathways. The pKa of a drug, which establishes its ionization state, can impact its solubility and absorption, thereby influencing metabolism.
The drug's acidity or basicity is essential in determining the metabolic...
The drug's acidity or basicity is essential in determining the metabolic...
Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...

